In keeping with the rodent literature, the application of TRPV4 agonists or antagonists enhanced or inhibited human visceral nociceptor activity, respectively.17 Combined with studies showing endogenous lipid mediators, which stimulate TRPV4, are elevated in IBS,25 our data suggest that TRPV4 antagonists could be clinically effective in IBS. This evidence concerns the gene TRPV4 and irritable bowel syndrome.